IONS Ionis Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Ionis Pharmaceuticals is trading 4.1% down today after pelacarsen’s failed Phase 3 cardiovascular-outcomes trial
Ionis Pharmaceuticals is trading 4.1% down at $44.84 as investors continue reassessing pelacarsen’s commercial and pipeline impact after its failed Phase 3...
🟢 Ionis Pharmaceuticals is trading 5% up today as biotech and major U.S. indexes rally
Ionis Pharmaceuticals is trading 4.96% up at $47.06, primarily as broader risk appetite lifts biotech and major U.S. indexes. - Rebounding after four...
🔴 Ionis Pharmaceuticals is trading 4% down today after pelacarsen’s Phase 3 cardiovascular endpoint failure
Ionis Pharmaceuticals is trading 4% down at $45.36 after investors continued reassessing partner Novartis’ September 4 announcement that pelacarsen’s Phase 3...
🔴 Ionis Pharmaceuticals is trading 4% down today after pelacarsen’s Phase 3 trial missed its cardiovascular endpoint
Ionis Pharmaceuticals is trading 4% down at $49.37 amid continued investor reassessment of partner Novartis’ September 4 announcement that pelacarsen’s Phase 3...
đź”´ Ionis Pharmaceuticals is trading 4.2% down today after pelacarsen Phase 3 study misses primary cardiovascular endpoint
Ionis Pharmaceuticals is trading 4.2% down now at $51.96 as investors continue reassessing partner Novartis’ September 4 announcement that pelacarsen’s Phase 3...
California State Teachers Retirement System discloses massive 8,000% increase in Ionis stake
California State Teachers Retirement System (CalSTRS) has dramatically increased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), according to a new...
Ionis Lost Its Biggest Bet on Heart Disease — Can Its Remaining Pipeline Justify the Stock?
Shares of Ionis Pharmaceuticals continued their slide Monday, trading at $53.73 — down 7.5% on the day and roughly 37% below their ~$86 level before the July 9...
đź”´ Ionis Pharmaceuticals is trading 7.5% down today after pelacarsen trial failure compounds earlier setbacks
Ionis Pharmaceuticals is trading 7.5% down now at $53.73. This decline is primarily driven by the continued market reaction to the recent failure of the Phase...
đź”´ Ionis Pharmaceuticals is trading 11.5% down in pre-market after CARDIO-TTRansform failed its primary endpoint
Ionis Pharmaceuticals is trading 11.5% down at $51.40, with the decline appearing to extend pressure from the July 9 announcement that the Phase 3...
Ionis' Partnered Drug Pelacarsen Fails to Meet Primary Endpoint in Phase 3 Study
Ionis Pharmaceuticals announced that its partner, Novartis, reported that the Phase 3 Lp(a)HORIZON study for the drug pelacarsen did not meet its primary...
đź”´ Ionis Pharmaceuticals is trading 13% down in after-hours trading despite FDA approval of ZANVASTRO
Ionis Pharmaceuticals is trading 12.55% down at $50.80, after closing at $58.09 on September 4, 2026; the decline follows FDA approval of ZANVASTRO for...
Ionis Pharmaceuticals Receives FDA Approval for ZANVASTRO™ for Alexander Disease
Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment of Alexander disease...
đź”´ Ionis Pharmaceuticals is trading 4.8% down today without a new company-specific catalyst
Ionis Pharmaceuticals is trading at $58.39, down 4.79%, without a new company-specific catalyst identified for September 3, 2026. - Ionis’s...
🔴 Ionis Pharmaceuticals is trading 4.2% down in pre-market — no clear company-specific catalyst identified
Ionis Pharmaceuticals is trading 4.2% down at $58.75 after closing at $61.33 on September 2, 2026; no clear company-specific catalyst was identified. - Ionis...
đź”´ Ionis Pharmaceuticals is trading 4.23% down in after-hours trading with no clear company-specific catalyst identified
Ionis Pharmaceuticals is trading 4.23% down at $58.74 after closing at $61.34 on September 2, 2026, with no clear company-specific catalyst identified. - No...